NICB

Research Interests:

Monoclonal Antibody Technology, Multiple Drug resistance (breast cancer, B cell malignancies), novel cancer associated antigens

Selected Peer Reviewed Journals

• Walsh N, Larkin A, Swan N, Conlon K, Dowling P, McDermott R, Clynes M. 2011. RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation. Cancer Letters, 306 (2),, pp180-190.
• Walsh N, Kennedy S, Larkin AM, Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I, Collins D, Ballot J, Ooi WS, Gullo G, Clynes M, Crown J, O'Driscoll L.. 2010. Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis.. British Journal Of Cancer, 102, 7, pp1157-1162.
• Walsh N *, Larkin A *, Kennedy S, Connolly L, Ballot J, Ooi W, Gullo G, Crown J, Clynes M, O' Driscoll L.. 2009. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma.. Bmc Urology, 9, 6
• O'Connor R, O'leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M and Crown J. 2007. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemotherapy And Pharmacology, 59, , pp79-87.
• O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J, Kennedy S. 2007. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma.. Anticancer Research, 27, 4B, pp2115-2120.
• Roy S, Kenny E, Kennedy S, Larkin A, Ballot J, De Villarreal MP, Crown J, O'Driscoll L. 2007. MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. Anticancer Research, 27, 3A, pp1325-1330.
• Matthews C, Catherwood MA, Larkin A, Clynes M, Morris TCM and Alexander HD. 2006. MDR-1, but not MDR-3 gene expression is associated with unmutated IgVh genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukaemia. Leukemia And Lymphoma, 47, , pp2308-2313.
• Larkin A, Moran E, Kennedy SM and Clynes M. 2005. Monoclonal antibody 5C3 raised against formalin fixed paraffin-embedded invasive breast tumour tissue: characterisation of its reactive antigen via immunoprecipitation and internal sequencing. Journal Of Immunological Methods, 303, , pp53-65.
• Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M and Clynes M. 2004. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. International Journal Of Cancer, 112, , pp286-294.
• O'Connor R, Heenan M, Connolly L, Larkin A and Clynes M. 2004. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Research, 24, , pp457-464.
• O'Driscoll L, Cronin D, Kennedy SM, Purcell R, Linehan R, Glynn S, Larkin A, Scanlon K, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M and Clynes M. 2004. Expression and prognostic relevance of Mcl-1 in breast cancer. Anticancer Research, 24, , pp473-482.
• Moran E, O'Keeffe M, O'Connor R, Larkin AM, Murphy P and Clynes M. 2002. Methods for generation of monoclonal antibodies to the very small drug hapten, 5-benzimidazolecarboxylic acid. Journal Of Immunological Methods, 271, , pp65-75.
• Connolly L, Moran E, Larkin A, Scheffer G, Scheper R, Sarkadi B, Kool M and Clynes M. 2001. A new monoclonal antibody, P2A8(6), that specifically recognizes a novel epitope on the multidrug resistance-associated protein 1 (MRP1), but not on MRP2 nor MRP3. Hybridoma And Hybridomics, 20, , pp333-341.
• Hill BT, Moran E, Etievant C, Perrin D, Masterson A, Larkin A and Whelan RD. 2000. Low-dose twice-daily fractionated X-irradiation of ovarian tumor cells in vitro generates drug-resistant cells overexpressing two multidrug resistance-associated proteins, P-glycoprotein and MRP1. Anti-cancer Drugs, 20, , pp193-200.
• Larkin A, Moran E, Alexander D and Clynes M. 1999. Preliminary immunocytochemical studies of MDR-1 and MDR-3 Pgp expression in B-cell leukaemias. Advances In Experimental Medicine And Biology, 457, , pp65-70.
• Larkin A, Moran E, Alexander D, Doherty G, Connolly L, Kennedy SM and Clynes M. 1999. A new monoclonal antibody that specifically recognises the MDR-3-encoded gene product. International Journal Of Cancer, 80, , pp265-271.
• Dunne BM, McNamara M, Clynes M, Shering SG, Larkin AM, Moran E, Barnes C and Kennedy SM. 1998. MDR1 expression is associated with adverse survival in melanoma of the uveal tract. Human Pathology, 29, , pp594-598.
• Moran E, Larkin A, Cleary I, Barnes C, Kennedy SM, Kelehan P and Clynes M. 1998. Monoclonal antibodies raised to paraffin wax embedded archival tissue; feasibility study of their potential to detect novel antigenic markers. Journal Of Immunological Methods, 219, , pp151-159.
• Moran E, Cleary I, Larkin AM, Amhlaoibh RN, Masterson A, Scheper RJ, Izquierdo MA, Center M, O'Sullivan F and Clynes M. 1997. Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42. European Journal Of Cancer, 33, , pp652-660.
• Moran E, Larkin A, Doherty G, Kelehan P, Kennedy S and Clynes M. 1997. A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections. Journal Of Clinical Pathology, 50, , pp465-471.

Selected Chapters

• Annemarie Larkin, Elizabeth Moran, Denis Alexander & Martin Clynes. 1999. Preliminary Immunocytochemical Studies of MDR-1 and MDR-3 Pgp Expression in B-cell Leukaemias. Drug Resistance in Leukaemia and Lymphoma III, pp65-70.
• Moran E, Larkin AM, Masterson A, Clynes M. 1998. Generation of Monoclonal Antibodies and Characterisation of Novel Antibodies by Western Blotting and Immunocytochemistry. Animal Cell Culture Techniques, pp82-104.

• , , , - ,
• , , , - ,
• Larkin A, MAbs for the Identification of Novel Cancer Associated Antigens, Ulster Immunology Research Group Meeting Feb 2009, 27-FEB-09 - 02-FEB-09, Queens University Belfast
• O'Sullivan D, Joyce H, Dowling P, Clynes M & Larkin A., Development of Monoclonal Antibodies for the Identification of Novel >>Invasion Associated targets in Human Cancer , European Association for Cancer Research annual meeting 2008, 07-MAY-08 - 07-AUG-08, Lyon, France
• Walsh N, Kennedy S, Larkin A, Roy S, Ooi W, Gullo G, Ballot J, Clynes M, Crown J, O'Driscoll L, MDR1/P-Glycoprotein and MRP-1 Protein Expression in Pancreatic (CaP) & Non-Small Cell Lung Cancers (NSCLC)., 31st ESMO Congress, 29-SEP-06 - 03-OCT-06, Istanbul
• O'Sullivan D, Joyce H, Clynes M and Larkin A., Generation and preliminary Characterisation of MAbs raised to the invasive breast cell line, MDA-MB-435-SF., International conference on Global mRNA and protein analysis., 07-SEP-06 - 08-SEP-06, Dublin City University.
• Roy, S; Kenny, E; Kennedy, S, et al., MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer, International Conference on Global mRNA and Protein Analysis, 07-SEP-06 - 08-SEP-06, Dublin City University, 1325 - 1325
• O'Sullivan, D; Breen, L; Larkin, A, et al, Comparison of in vitro invasion assay methods for characterisation of human breast and melanoma cancer cell lines, In: : ANTICANCER RESEARCH Volume: 27 Issue: 3A Published: MAY-JUN 2007 ed.International Conference on Global mRNA and Protein Analysis, 07-SEP-06 - 08-SEP-06, Dublin City University., 1384 - 1384
• Alexander HD, Matthews C, Catherwood MA, Larkin A, Clynes M, Morris TCM, MDR-1, BUT NOT MDR-3 GENE EXPRESSION, IS ASSOCIATED WITH UNMUTATED IGVH GENES AND POOR PROGNOSIS CHROMOSOMAL ABERRATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA, 11th Congress of the European Haematology Association, 15-JUN-06 - 18-JUN-06, Amsterdam
• Larkin A, Moran E, Adams A and Clynes M. , MDR-3 PgP Expression in Invasive Breast Cancer. , Biotechnology, Cancer and Drug resistance. , 07-AUG-03 - 08-AUG-03, Clontarf Castle, Dublin.
• Larkin A, Moran E, Kennedy S and Clynes M. , Investigation of Multiple Drug Resistance (MDR) protein levels in pre and post treatment samples from breast cancer patients. , Joint Meeting Irish Association of Cancer Research & British Association for Cancer Research, Trinity College Dublin. , 20-JUN-98 - 22-JUN-98, Trinity college, Dublin.
• Larkin A, Moran, Alexander HD and Clynes M. , Preliminary Immunocytochemical Studies of MDR-1 and MDR-3 Pgp Expression in B-cell leukaemias. , 3rd International Symposium on Drug Resistance in Leukaemia and Lymphoma. , 04-MAR-98 - 07-MAR-98, Amsterdam.
• Parums DV, Chung N and Larkin AM., Interleukin (IL) -2 and IL-4 are involved in progression of human atherosclerosis., 173 rd Meeting of the Pathological Society of Great Britan and Ireland., 10-JUL-96 - 12-JUL-96, Southampton.
• Moran, E.; Cleary, I.; Larkin, A. M., et al., Differential expression of MDR-associated markers and cytoskeletal proteins in variants of a human ovarian carcinoma cell line, In: Cytotechnology ed.ETCS (European Tissue Culture Society) Meeting on Drug Resistance in Cancer,, 20-SEP-95 - 23-SEP-95, Dublin City University, 269 - 269
• Moran, E.; Larkin, A. M.; Woodman, A., et al., Antibodies generated to synthetic peptides specifically recognise their target antigens (P-170 and topoisomerase II-alpha) by immunohistochemical techniques and Western blotting, In: Cytotechnology ed.ETCS (European Tissue Culture Society) Meeting on Drug Resistance in Cance, 20-SEP-95 - 23-SEP-95, Dublin City University, 263 - 263
• Larkin AM and Parums DV. , The Expression of IL-2 and IL-4 in inflammation associated with advanced atherosclerosis using non isotopic in situ hybridisation (NISH). , Pathological Society of Great Britan and Ireland summer meeting. , 14-JUN-94 - 16-JUN-94, Glasgow.